Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication
Amgad M. Rabie
Abstract
of about 2 μM, edging over both remdesivir and its active metabolite GS-441524. The ideal pharmacophoric features of the cordycepin molecule render it a typical inhibitor of SARS-CoV-2 replication, with its flexible structure open for most types of derivatization in the future. Briefly, the current findings further support and suggest the repurposing possibility of cordycepin against COVID-19 and greatly encourage us to confidently and rapidly begin its preclinical/clinical evaluations for the comprehensive treatment of COVID-19.
Topics & Concepts
CordycepinChemistryNatural productPharmacologyNucleosideBiochemistryAdenosineDrugRepurposingDrug repositioningBiological activityCoronavirusDrug discoveryInhibitory postsynaptic potentialVirusViral replicationStructure–activity relationshipMetaboliteBiologyMechanism of actionNucleic acidMode of actionPharmacological Receptor Mechanisms and EffectsCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19